Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc is a biotechnology firm currently in the clinical trial phase committed to devising and introducing treatments for individuals affected by severe cannabinoid poisoning and various forms of substance dependency Its leading experimental drug ANEB001 is a small molecule engineered to counteract cannabinoid receptors specifically targeting both cannabinoid intoxication and overdose The company was founded in 2020 and maintains its headquarters in Lakeway Texas